




RealRate

PHARMACEUTICAL 2015

Oncomed Pharmaceuticals Inc
Rank 187 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncomed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncomed Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Oncomed Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 61% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	240,810
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	38,546
Liabilities, Non-Current	0
Other Assets	1,928
Other Compr. Net Income	-31
Other Expenses	-509
Other Liabilities	132,929
Other Net Income	105
Other Revenues	39,559
Property and Equipment	5,104
Research and Development	76,430
Selling, General and Administrative Expense	13,753

Output Variable	Value in 1000 USD
Assets	247,842
Liabilities	171,475
Expenses	89,674
Revenues	39,559
Stockholders Equity	76,367
Net Income	-50,010
Comprehensive Net Income	-50,026
BaseVar	274,343
ECR before Limited Liability	56%
Economic Capital Ratio	193%